CLINICAL_TRIALS
trial_result
· 2015-11-09
Clinical Trial Update: Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients [Phase 2]
Summary
Phase 2 trial evaluating AVI-4658 to induce dystrophin expression in Duchenne Muscular Dystrophy patients has completed with results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2015-11-09